A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases

As a novel third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI), Aumolertinib has demonstrated remarkable efficacy in patients with EGFR mutations and asymptomatic CNS metastases. However, the treatment of symptomatic brain metastases remains challenging due to poor quality of life and overall survival outcomes. There is no available data on the efficacy of Aumolertinib for this patient population. Therefore, this study aimed to assess efficacy of the symptomatic brain metastases patients who treated aumolertinib combined or not with local treatment.